Last reviewed · How we verify
Angiogenic Cell Precusors — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Angiogenic Cell Precusors (Angiogenic Cell Precusors) — TheraVitae Ltd.. Autologous cell therapy designed to promote angiogenesis and neovascularization in ischemic tissues.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Angiogenic Cell Precusors TARGET | Angiogenic Cell Precusors | TheraVitae Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Angiogenic Cell Precusors CI watch — RSS
- Angiogenic Cell Precusors CI watch — Atom
- Angiogenic Cell Precusors CI watch — JSON
- Angiogenic Cell Precusors alone — RSS
Cite this brief
Drug Landscape (2026). Angiogenic Cell Precusors — Competitive Intelligence Brief. https://druglandscape.com/ci/angiogenic-cell-precusors. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing